A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

NCT06441812 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Asthma Patients

Interventions

DRUG: SHR-1703 Injection

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd